PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 29 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 29 of 32

5 votes 5 answers12k views
Is there any published stability data for orforglipron at minus 80 °C?

What I am working with: orforglipron · minus 80 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by marcus_thorbjorn 9.4k · 17 months ago
5 votes5 answers11k views
What does SURMOUNT-3 report at the 15 mg dose level?

Stated plainly: SURMOUNT-3 · 15 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by lucia_marchetti 19k · 16 months ago
5 votes5 answers7.4k views
Is there any published stability data for semaglutide at minus 80 °C?

Concretely: semaglutide · minus 80 °C. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by fiadh_cronin 58k · 2.0 years ago
5 votes 5 answers5.2k views
What did the placebo arm of SURMOUNT-OSA report for hair thinning?

What I am working with: SURMOUNT-OSA · hair thinning. This is presented as though it settles something, and I am not convinced it does. I have two documents that…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
asked by ten_mg_vial 31k · 8 months ago
5 votes 5 answers3.9k views
What does SURMOUNT-3 report at the 10 mg dose level?

What I have: SURMOUNT-3 · 10 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by cold_lane 10k · 27 days ago
5 votes0 answers3.8k views
What does SURMOUNT-3 tell me about vomiting at the 10 mg dose?

Concretely: SURMOUNT-3 · vomiting · 10 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by tyndall_haze 38k · 22 months ago
5 votes 2 answers3.2k views
What is the reported incidence of headache on semaglutide in STEP 2?

Setup, so nobody has to ask: headache · semaglutide · STEP 2. I have read the primary source rather than the summary, which has left me with more questions. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by helena_vidmar 8.5k · 5 months ago
5 votes3 answers2.4k views
What is the reported incidence of headache on semaglutide in STEP 3?

The case in front of me: headache · semaglutide · STEP 3. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by Dr_Signe_Baldursdottir 29k · 4 months ago
4 votes5 answers28k views
Does testosterone recover on weight loss alone in men?

I have three data points across nine months, which I hope is enough to see a trend. I would like to know whether this claim survives contact with evidence. If the…

hormones
hormones

Endocrine changes accompanying substantial weight loss: sex hormone binding globulin, testosterone, oestradiol, cortisol and the reproductive…

13 questions
bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by tare_and_weigh 12k · 2.3 years ago
4 votes5 answers22k views
What is the reported incidence of reflux on semaglutide in SUSTAIN-6?

The specifics, since they change the answer: reflux · semaglutide · SUSTAIN-6. I have the document in front of me and I can read the numbers. What I cannot do is…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by Dr_Jonas_Halvorsen 28k · 23 months ago
4 votes5 answers19k views
What is the lowest maintenance dose with published maintenance data behind it?

I have been on a stable schedule for eleven weeks, so this is not a first-week question. I am asking for verification rather than opinion, ideally with something I…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
weight-regain
weight-regain

Regain after stopping or reducing: the trajectory reported in the withdrawal extensions, how much is fluid, and what the maintenance arms tell us…

10 questions
asked by claudia_ferrante 22k · 2.3 years ago
4 votes 4 answers19k views
What is the reported incidence of dizziness on oral semaglutide in PIONEER-1?

What I have: dizziness · oral semaglutide · PIONEER-1. This is presented as though it settles something, and I am not convinced it does. I have two documents that…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by swirl_dont_shake 10k · 2.1 years ago
4 votes 5 answers18k views
What is the reported incidence of dizziness on tirzepatide in SURMOUNT-5?

The specifics, since they change the answer: dizziness · tirzepatide · SURMOUNT-5. I want to understand what this actually establishes, as opposed to what it is being…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by mg_per_ml 15k · 2.1 years ago
4 votes 5 answers15k views
What does STEP 3 report at the 2 mg dose level?

Setup, so nobody has to ask: STEP 3 · 2 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by yuki_morishita 10k · 13 months ago
4 votes 5 answers8.7k views
What does SURMOUNT-2 tell me about vomiting at the 10 mg dose?

Setup, so nobody has to ask: SURMOUNT-2 · vomiting · 10 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by coring_risk 27k · 9 months ago
4 votes 5 answers7.9k views
What did STEP 8 do with participants who could not tolerate a step?

I have been on a stable schedule for eleven weeks, so this is not a first-week question. I have the document in front of me and I can read the numbers. What I cannot…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by thabo_maseko 28k · 20 months ago
4 votes 5 answers7.1k views
What does TRIUMPH-1 report at the 8 mg dose level?

For reference: TRIUMPH-1 · 8 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by fiadh_cronin 58k · 21 months ago
4 votes0 answers7k views
What is the reported incidence of vomiting on tirzepatide in SURMOUNT-OSA?

The particulars: vomiting · tirzepatide · SURMOUNT-OSA. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by mala_venkatesh 22k · 23 months ago
4 votes0 answers6.4k views
How comparable are liraglutide and survodutide on the evidence available?

Details up front: liraglutide · survodutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
asked by priya_menon 13k · 23 months ago
4 votes5 answers6.1k views
How do I convert the STEP 1 hazard ratio into an absolute risk reduction?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. Please show the division. I want to check my own against yours. I…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by jana_horakova 10k · 9 months ago
4 votes4 answers6.1k views
Is STEP 8 a fair comparison of semaglutide against its comparator arm?

Concretely: STEP 8 · semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Has anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by lucia_marchetti 19k · 14 months ago
4 votes 5 answers5k views
What does SURMOUNT-2 actually establish about tirzepatide?

The particulars: SURMOUNT-2 · tirzepatide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by kelvin_lam 7.6k · 5 months ago
4 votes3 answers4.6k views
Is SUSTAIN-6 a fair comparison of semaglutide against its comparator arm?

Numbers first: SUSTAIN-6 · semaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by Dr_Ravi_Selvarajah 35k · 6 months ago
4 votes0 answers4.6k views
What does STEP 8 tell me about nausea at the 2 mg dose?

For reference: STEP 8 · nausea · 2 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by greta_holzmann 23k · 19 months ago